DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA-IV - POSSIBLE CAUSES OF LOW BIOAVAILABILITY OF ORAL LEVODOPA IN DOGS

被引：30

作者：

SASAHARA, K

NITANAI, T

HABARA, T

KOJIMA, T

KAWAHARA, Y

MORIOKA, T

NAKAJIMA, E

机构：

来源：

JOURNAL OF PHARMACEUTICAL SCIENCES | 1981年 / 70卷 / 07期

关键词：

D O I：

10.1002/jps.2600700705

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：730 / 733

页数：4

共 14 条

[1]

BAKKE OM, 1971, ACTA PHARMACOL TOX, V29, P106

[2]

BARBEAU A, 1971, CLIN PHARMACOL THER, V12, P353

[3] MODERN TREATMENT OF PARKINSONISM [J].

BIRKMAYER, W ;

NEUMAYER, E .

ZEITSCHRIFT FUR NEUROLOGIE, 1972, 202 (04) :257-+

[4]

BORUD O, 1971, ACTA PHARMACOL TOX, V30, P185

[5]

COTLER S, 1976, J PHARM SCI, V65, P824

[6]

GOLDIN BR, 1971, J PHARMACOL EXP THER, V186, P160

[7]

GOLDMAN P, 1974, AM J CLIN NUTR, V27, P1368

[8] ROLE OF LIVER IN CLEARANCE OF L-DOPA FROM PLASMA [J].

MEARRICK, PT ;

GRAHAM, GG ;

WADE, DN .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1975, 3 (01) :13-23

[9]

MILLER EM, 1972, NEUROLOGY, V5, P482

[10]

PLETSCHER A, 1971, CLIN PHARMACOL THER, V12, P344

← 1 2 →